BioWorld

Nov. 16, 2005

FDA Sends Second Approvable Letter For Celgene's Thalomid

Celgene Corp.'s Thalomid (thalidomide) again is approvable for multiple myeloma, but only after certain conditions are met, the FDA said. (BioWorld Today) Read More

AVI Brings In $23M For Third-Generation Antisense Drugs

Korea Touts Itself As Growth Region For Biotech Investing

Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...